Chemical Name: N-[1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide
Biological ActivityAVE 1625 is a potent and selective CB1 receptor antagonist (IC50 values are 25 and 10 nM for human and rat CB1R, respectively). Exhibits >400-fold selectivity for CB1 over CB2 receptors. Attenuates Olanzapine (Cat. No. 4349) induced weight gain and food intake in rats with no effect on energy expenditure or motility. Also improves cognitive function in rodent schizophrenia models and ameliorates extrapyramidal side-effects of antipsychotics.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.
Herling et al.
Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
Liebig et al.
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Black et al.
Psychopharmacology (Berl.), 2011;215:149
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for AVE 1625
There are currently no reviews for this product. Be the first to review AVE 1625 and earn rewards!
Have you used AVE 1625?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image